 Connection
Michail Mavros to Adenocarcinoma
This is a "connection" page, showing publications Michail Mavros has written about Adenocarcinoma.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.333 |
|
|
|
-
Mavros MN, Davis LE, Hallet J, Tung S, Mahar AL, Bubis LD, Hammad A, Zhao H, Earle CC, Barbera L, Coburn NG. Symptom Burden of Nonresected Pancreatic Adenocarcinoma: An Analysis of 10,753 Patient-Reported Outcome Assessments. Pancreas. 2020 09; 49(8):1083-1089.
Score: 0.557
-
Mavros MN, Coburn NG, Davis LE, Mahar AL, Liu Y, Beyfuss K, Myrehaug S, Earle CC, Hallet J. Low rates of specialized cancer consultation and cancer-directed therapy for noncurable pancreatic adenocarcinoma: a population-based analysis. CMAJ. 2019 05 27; 191(21):E574-E580.
Score: 0.510
-
Hallet J, Davis L, Mahar A, Mavros M, Beyfuss K, Liu Y, Law CHL, Earle C, Coburn N. Benefits of High-Volume Medical Oncology Care for Noncurable Pancreatic Adenocarcinoma: A Population-Based Analysis. J Natl Compr Canc Netw. 2020 03; 18(3):297-303.
Score: 0.134
-
Tung S, Davis LE, Hallet J, Mavros MN, Mahar AL, Bubis LD, Hammad A, Zhao H, Earle CC, Barbera L, Coburn NG, Siqqidui M, Li Q, Elmi M, Shin E, Hsieh E, Goyert N. Population-Level Symptom Assessment Following Pancreaticoduodenectomy for Adenocarcinoma. JAMA Surg. 2019 11 01; 154(11):e193348.
Score: 0.131
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|